Natco launches Alphalan to treat multiple myeloma

By E. Janene Geiss

Philadelphia, Dec. 8 - Natco Pharma Ltd. announced Thursday the launch of Alphalan (melphalan) in 2 mg and 5 mg tablets.

The launch of this cytotoxic drug represents the introduction of this niche product to India. It is the only product available in the market for the treatment of multiple myeloma, a form of blood cancer, according to a company news release.

Multiple myeloma affects the plasma cell, which is an important part of the immune system. Malignant plasma cells accumulate and damage the bone marrow in the spine, pelvis, rib cage and skull of patients, company officials said.

Natco said the product is affordable and available in packs of 25 tablets each, in both 2 mg and 5 mg forms.

Natco is a Hyderabad, India, pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.